

## APPENDIX

VERSION OF SPECIFICATION AND CLAIMS  
WITH MARKINGS TO SHOW CHANGES MADEIn the Specification:

At page 1, line 1 of the specification, please insert the following new sentence:

5      Statement of Government Support:


This invention was made with government support under Contract No. CA55276 by the National Institutes of Health. The government has certain rights in the invention.

10     In the Claims:

Please cancel claims 2-18 without prejudice.

Please amend Claim 1 and add new claims 19-31 as follows:


- 15     1. (once amended) A [method] process for [the synthesis] synthesizing a dihydroindole C-ring of a CC-1065/duocarmycin analog, the dihydroindole C-ring of a CC-1065/duocarmycin analog being represented by the following structure:



20     [wherein the method comprises] the process comprising the following steps [of]:

Step A: allylating an [aryl halide] ortho-haloaniline with 1,3-dichloropropene [and a catalytic amount of *n*-tetrabutylammonium iodide] for forming a vinyl chloride, the ortho-haloaniline being represented by the following structure:


## APPENDIX

VERSION OF SPECIFICATION AND CLAIMS  
WITH MARKINGS TO SHOW CHANGES MADE

wherein:

$R^1$ ,  $R^2$ ,  $R^3$ , and  $R^4$  are radicals independently selected from the group consisting of hydrogen, alkyl(C1-C6), alkoxy, and arylalkoxy, with a proviso that  $R^1$  and  $R^2$ , or  $R^2$  and  $R^3$  may form a fused 5- or 6-membered ring with or without a heteroatom; and

$X$  is a halide selected from the group consisting of bromine and iodine; and the vinyl chloride is represented by the following structure:



then

Step B: cyclizing the vinyl chloride of said step A [under conditions using tributyl tin hydride, catalytic AIBN and toluene as the solvent] for forming the dihydroindole C-ring of the CC-1065 / duocarmycin analog.

19. (new claim) A process according to claim 1 wherein, in said Step A, the *ortho*-haloaniline is an *ortho*-bromoaniline.

20. (new claim) A process according to claim 1 wherein, in said Step A, the *ortho*-haloaniline is an *ortho*-iodoaniline.

21. (new claim) A process according to claim 1 wherein, in said Step A, the *ortho*-haloaniline is protected with a BOC group.

## APPENDIX

VERSION OF SPECIFICATION AND CLAIMS  
WITH MARKINGS TO SHOW CHANGES MADE

22. (new claim) A process according to claim 1 wherein, in said Step A, said allylation is catalyzed by the addition of a catalytic amount of tetra-*n*-butyl ammonium iodide.


23. (new claim) A process according to claim 1 wherein, in said Step B, said cyclization is performed with an addition of tri-*n*-butyltin hydride.

24. (new claim) A process according to claim 23 wherein, in said Step B, said cyclization is catalyzed by the addition of a catalytic amount of AIBN.


25. (new claim) A process according to claim 24 wherein, in said Step B, said cyclization is performed using toluene as the solvent.

26. (new claim) A process according to claim 1 wherein:

in said Step A, the vinyl chloride is represented by the following structure:



in said Step B, the dihydroindole C-ring of the CC-1065 / duocarmycin analog is represented by the following structure:




## APPENDIX


VERSION OF SPECIFICATION AND CLAIMS  
WITH MARKINGS TO SHOW CHANGES MADE

27. (new claim) A process according to claim 1 wherein:

in said Step A, the vinyl chloride is represented by the following structure:




in said Step B, the dihydroindole C-ring of the CC-1065 / duocarmycin analog is represented by the following structure:




28. (new claim) A process according to claim 1 wherein:

in said Step A, the vinyl chloride is represented by the following structure:



in said Step B, the dihydroindole C-ring of the CC-1065 / duocarmycin analog is represented by the following structure:




## APPENDIX


VERSION OF SPECIFICATION AND CLAIMS  
WITH MARKINGS TO SHOW CHANGES MADE

29. (new claim) A process according to claim 1 wherein:

in said Step A, the vinyl chloride is represented by the following structure:




10 in said Step B, the dihydroindole C-ring of the CC-1065 / duocarmycin analog is represented by the following structure:




30. (new claim) A process according to claim 1 wherein:

in said Step A, the vinyl chloride is represented by the following structure:



25 in said Step B, the dihydroindole C-ring of the CC-1065 / duocarmycin analog is represented by the following structure:




## APPENDIX

VERSION OF SPECIFICATION AND CLAIMS  
WITH MARKINGS TO SHOW CHANGES MADE

31. (new claim) A process according to claim 1 wherein:

in said Step A, the vinyl chloride is represented by the following structure:



10

in said Step B, the dihydroindole C-ring of the CC-1065 / duocarmycin analog is represented by the following structure:

